{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    5,
    45
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 0.7,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_6",
        "affectedSection": "Section 6.5.1 - COVID-19 Vaccination",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated guidance on participant unblinding for the purpose of receiving COVID-19 vaccinations and subsequent study participation."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_6",
        "affectedSection": "Section 6.3.3 - Procedures for Unblinding",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarified the process for unblinding participants who wish to be vaccinated."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_6",
        "reasonText": "To provide clinical guidance and counseling for participants wishing to receive a SARS-CoV-2 vaccine after recovery from COVID-19.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_6",
        "reasonText": "To address potential interference between AZD7442 monoclonal antibodies and vaccine-induced immune responses.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.5.1",
        "afterText": "Participants may wish to be vaccinated. If so, they may be unblinded as to their randomized investigational treatment in this study as per study unblinding procedure (Section 6.3.3), counselled, and referred outside the study for possible vaccination.",
        "summary": "Added provision for unblinding participants for vaccination purposes."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_6",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.5.1",
        "afterText": "Unblinded participants who received AZD7442 should be advised to consider waiting an appropriate length of time (9 to 12 months) before receiving an anti-SARS-CoV-2 vaccine.",
        "summary": "Specified waiting period for vaccination for participants in the AZD7442 arm to avoid potential interference."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_6",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.5.1",
        "afterText": "Participants who have been unblinded in order to receive vaccination can and should remain in the study after being unblinded.",
        "summary": "Confirmed that unblinded participants should continue study follow-up."
      }
    ],
    "summary": {
      "impactCount": 2,
      "reasonCount": 2,
      "changeCount": 3
    }
  }
}